Agilent Technologies, Inc.
NYSE:AMedical - Diagnostics & Research
+$3.04 today
- Market cap
- $50.00B
- Beta
- 1.26
- P/E (TTM)
- 25.5
- EPS (TTM)
- $5.00
- Dividend yield
- 0.59%
Volume 2.48M
Average 2.24M
A Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Agilent Technologies, Inc.NYSE: A
Research & Development · Q3 FY2026 · quarter ended Jul 2026
Research & development growth accelerates
Q3 FY2026 research & development of $123M rose 10.8% year over year, ahead of the +8.5% change in trailing-twelve-month research & development. Sequentially, it fell 2.4% from the prior quarter. Over 3 fiscal years it compounded at -0.9% a year.
Context
- Research & development amounted to 6.5% of revenue in FY2025, down 0.8 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +10.8% holds above the trailing-twelve-month pace of +8.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 455M USD
- Year-over-year change
- -5.0%
- 4-year CAGR
- +0.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-10-31 | 455M | -5.0% |
| FY2024 | 2024-10-31 | 479M | -0.4% |
| FY2023 | 2023-10-31 | 481M | +3.0% |
| FY2022 | 2022-10-31 | 467M | +5.9% |
| FY2021 | 2021-10-31 | 441M | — |
Research & Development vs competitors
How A compares with its peers on the latest reported figures
- A's LTM Jul 2026 research & development of $485M is the 3rd highest of the 9 companies compared; the peer median is $291.42M.
- Its year-over-year change of +8.5% is the 2nd highest of 9, against a peer median of +4.7%.
- Research & development amounts to 6.6% of revenue for A, versus a peer median of 7.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.67B | +4.2% | +1.5% | 6.5% | |
| LTM Sep 2026 | $1.41B | -0.7% | -1.7% | 3.0% | |
| LTM Jul 2026 | $485M | +8.5% | -0.9% | 6.6% | |
| LTM Jun 2026 | $393.5M | -1.6% | +18.8% | 11.2% | |
| LTM Jul 2026 | $321.75M | +71.7% | +3.5% | 6.9% | |
| LTM Jun 2026 | $261.1M | -14.3% | +0.0% | 10.1% | |
| LTM Jul 2026 | $215.83M | +5.2% | -0.9% | 7.4% | |
| LTM Jun 2026 | $208.01M | +7.9% | +4.0% | 5.0% | |
| LTM Jun 2026 | $194.67M | +5.5% | -0.4% | 9.3% | |
| Peer median (excluding A) | $291.42M | +4.7% | +0.8% | 7.2% | |
Competitors are the stored peer set for A. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Oct 2021 | FY2022 Oct 2022 | FY2023 Oct 2023 | FY2024 Oct 2024 | FY2025 Oct 2025 |
|---|---|---|---|---|---|
| Revenue | 6.32B | 6.85B | 6.83B | 6.51B | 6.95B |
| Cost of Revenue | 2.91B | 3.13B | 3.37B | 2.98B | 3.31B |
| Gross Profit | 3.41B | 3.72B | 3.47B | 3.54B | 3.64B |
| Gross Margin | 53.9% | 54.4% | 50.7% | 54.3% | 52.4% |
| Research & Development | 441M | 467M | 481M | 479M | 455M |
| Selling, General & Admin | 1.62B | 1.64B | 1.63B | 1.52B | 1.71B |
| Operating Expenses | 2.06B | 2.1B | 2.12B | 2.05B | 2.16B |
| Depreciation & Amortization | 321M | 317M | 271M | 257M | 288M |
| EBITDA | 1.76B | 1.91B | 1.7B | 1.87B | 1.84B |
| EBITDA Margin | 27.9% | 27.8% | 24.9% | 28.8% | 26.4% |
| Operating Income | 1.35B | 1.62B | 1.35B | 1.49B | 1.48B |
| Operating Margin | 21.3% | 23.6% | 19.8% | 22.9% | 21.3% |
| Interest Income | 2M | 9M | 51M | 80M | 62M |
| Interest Expense | 81M | 84M | 95M | 96M | 112M |
| Other Income / Expenses | 13M | (114M) | (11M) | 33M | (44M) |
| Income Before Tax | 1.36B | 1.5B | 1.34B | 1.52B | 1.44B |
| Pre-Tax Margin | 21.5% | 22.0% | 19.6% | 23.4% | 20.7% |
| Income Tax Expense | 150M | 250M | 99M | 232M | 132M |
| Net Income | 1.21B | 1.25B | 1.24B | 1.29B | 1.3B |
| Net Margin | 19.1% | 18.3% | 18.1% | 19.8% | 18.8% |
| EPS (Basic) | 3.98 | 4.19 | 4.22 | 4.44 | 4.59 |
| EPS (Diluted) | 3.94 | 4.18 | 4.19 | 4.43 | 4.57 |
| Weighted Avg Shares | 304M | 299M | 294M | 290M | 283M |
| Weighted Avg Shares (Diluted) | 307M | 300M | 296M | 291M | 284M |
Agilent Technologies, Inc.
NYSE:A
Intrinsic Alpha fair value
Locked
Current Price
$177.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.